Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 85026
1. Gustafsson M, Sjölander M, Pfister B, Jonsson J, Schneede J, Lövheim H: Pharmacist participation in hospital ward teams and hospital readmission rates among people with dementia: a randomized controlled trial. Eur J Clin Pharmacol; 2017 Jul;73(7):827-835

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacist participation in hospital ward teams and hospital readmission rates among people with dementia: a randomized controlled trial.
  • PURPOSE: To assess whether comprehensive medication reviews conducted by clinical pharmacists as part of a healthcare team reduce drug-related hospital readmission rates among people with dementia or cognitive impairment.
  • Patients aged ≥65 years with dementia or cognitive impairment admitted to three wards at two hospitals located in Northern Sweden were included.
  • The primary outcome, risk of drug-related hospital readmissions, was assessed at 180 days of follow-up by intention-to-treat analysis.
  • CONCLUSION: Participation of clinical pharmacists in healthcare team conducting comprehensive medication reviews did not significantly reduce the risk of drug-related readmissions in patients with dementia or cognitive impairment; however, post-hoc and subgroup analyses indicated significant effects favoring the intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharm World Sci. 2006 Jun;28(3):152-8 [17004023.001]
  • [Cites] Am J Geriatr Pharmacother. 2003 Dec;1(2):82-9 [15555470.001]
  • [Cites] J Eval Clin Pract. 2007 Oct;13(5):781-8 [17824872.001]
  • [Cites] Ann Pharmacother. 2002 Jul-Aug;36(7-8):1238-48 [12086559.001]
  • [Cites] Res Social Adm Pharm. 2014 Jul-Aug;10(4):608-22 [24161491.001]
  • [Cites] Clin Drug Investig. 2010;30(5):289-300 [20384385.001]
  • [Cites] Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008986 [23450593.001]
  • [Cites] Arch Intern Med. 2009 May 11;169(9):894-900 [19433702.001]
  • [Cites] Arch Intern Med. 2008 Apr 14;168(7):687-94 [18413550.001]
  • [Cites] Med Care. 2010 Oct;48(10):923-33 [20720510.001]
  • [Cites] Cochrane Database Syst Rev. 2010 Jul 07;(7):CD000336 [20614422.001]
  • [Cites] Am J Geriatr Psychiatry. 2008 Jul;16(7):528-36 [18591573.001]
  • [Cites] Neurol Sci. 2009 Apr;30(2):87-92 [19229475.001]
  • [Cites] JAMA Intern Med. 2015 Nov;175(11):1803-12 [26368317.001]
  • [Cites] BMC Pharmacol Toxicol. 2013 Feb 08;14:10 [23391323.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):68-74 [15642877.001]
  • [Cites] Eur J Clin Pharmacol. 2016 Sep;72 (9):1143-53 [27377393.001]
  • [Cites] JAMA. 2015 Oct 27;314(16):1681-2 [26505584.001]
  • [Cites] J Patient Saf. 2015 Mar 4;:null [25742062.001]
  • [Cites] Arch Intern Med. 1990 Apr;150(4):841-5 [2327844.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2013 Jun;112(6):359-73 [23506448.001]
  • [Cites] JAMA. 1998 Apr 15;279(15):1200-5 [9555760.001]
  • [Cites] PLoS One. 2014 Nov 07;9(11):e112282 [25379675.001]
  • [Cites] J Manag Care Pharm. 2013 Jun;19(5):408-16 [23697478.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):173-84 [17630041.001]
  • [Cites] Eur Heart J. 2006 Feb;27(4):434-40 [16230302.001]
  • [Cites] J Am Geriatr Soc. 2010 Apr;58(4):627-35 [20398146.001]
  • [Cites] Intern Med J. 2001 May-Jun;31(4):199-205 [11456032.001]
  • (PMID = 28391409.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Clinical pharmacists / Dementia / Drug-related readmissions / Medication reviews / Old people
  •  go-up   go-down


2. Sommer I, Griebler U, Kien C, Auer S, Klerings I, Hammer R, Holzer P, Gartlehner G: Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis. BMC Geriatr; 2017 Jan 13;17(1):16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D deficiency as a risk factor for dementia: a systematic review and meta-analysis.
  • BACKGROUND: Sunlight exposure and high vitamin D status have been hypothesised to reduce the risk of developing dementia.
  • The objective of our research was to determine whether lack of sunlight and hypovitaminosis D over time are associated with dementia.
  • We conducted random effects meta-analyses of published and unpublished data to evaluate the influence of sunlight exposure or vitamin D as a surrogate marker on dementia risk.
  • RESULTS: We could not identify a single study investigating the association between sunlight exposure and dementia risk.
  • Six cohort studies provided data on the effect of serum vitamin D concentration on dementia risk.
  • The strength of evidence that serious vitamin D deficiency increases the risk of developing dementia, however, is very low due to the observational nature of included studies and their lack of adjustment for residual or important confounders (e.g.
  • ApoE ε4 genotype), as well as the indirect relationship between Vitamin D concentrations as a surrogate for sunlight exposure and dementia risk.
  • CONCLUSIONS: The results of this systematic review show that low vitamin D levels might contribute to the development of dementia.
  • Further research examining the direct and indirect relationship between sunlight exposure and dementia risk is needed.
  • Such research should involve large-scale cohort studies with homogeneous and repeated assessment of vitamin D concentrations or sunlight exposure and dementia outcomes.
  • [MeSH-major] Dementia / blood. Dementia / psychology. Sunlight. Vitamin D Deficiency / blood. Vitamin D Deficiency / psychology

  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Nutr Bull. 2014 Dec;39(4):322-350 [25635171.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1277-82 [21802904.001]
  • [Cites] J Alzheimers Dis. 2013;33(3):659-74 [23042216.001]
  • [Cites] Ann N Y Acad Sci. 2016 Mar;1367(1):57-63 [27116242.001]
  • [Cites] Neurology. 2012 Sep 25;79(13):1397-405 [23008220.001]
  • [Cites] Syst Rev. 2015 Jan 01;4:1 [25554246.001]
  • [Cites] J Clin Epidemiol. 2011 Apr;64(4):407-15 [21247734.001]
  • [Cites] Front Mol Neurosci. 2015 Oct 07;8:58 [26468295.001]
  • [Cites] J Clin Epidemiol. 2010 May;63(5):474-5 [20189352.001]
  • [Cites] J Alzheimers Dis. 2014;42 Suppl 3:S53-61 [24898645.001]
  • [Cites] Eur J Neurol. 2014 Sep;21(9):1211-8, e69-70 [24846449.001]
  • [Cites] Epidemiology. 2014 Nov;25(6):799-804 [25215530.001]
  • [Cites] Neurology. 2014 Sep 2;83(10):920-8 [25098535.001]
  • [Cites] Eur J Clin Nutr. 2013 Mar;67(3):270-4 [23388663.001]
  • [Cites] PLoS One. 2013 Jun 21;8(6):e65785 [23805188.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1294-302 [21803546.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1311-6 [21802902.001]
  • [Cites] Lancet Neurol. 2016 Jan;15(1):116-24 [26300044.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1283-93 [21839614.001]
  • [Cites] J Chem Neuroanat. 2005 Jan;29(1):21-30 [15589699.001]
  • [Cites] J Cereb Blood Flow Metab. 2016 Jan;36(1):172-86 [26174330.001]
  • [Cites] Stroke. 2006 Feb;37(2):345-50 [16397184.001]
  • [Cites] Osteoporos Int. 2009 Nov;20(11):1807-20 [19543765.001]
  • [Cites] Clin Chem. 2012 Mar;58(3):531-42 [22230812.001]
  • [Cites] Alzheimers Dement. 2014 May;10(3):296-302 [23871764.001]
  • [Cites] Dement Geriatr Cogn Disord. 2011;32(4):273-8 [22261995.001]
  • [Cites] Am J Epidemiol. 2010 Apr 15;171(8):903-8 [20219763.001]
  • [Cites] J Bone Miner Res. 2012 Jun;27(6):1381-9 [22407786.001]
  • [Cites] Evid Rep Technol Assess (Full Rep). 2010 Apr;(193):1-727 [21500874.001]
  • [Cites] J Clin Epidemiol. 2011 Apr;64(4):401-6 [21208779.001]
  • [Cites] Am J Geriatr Pharmacother. 2010 Feb;8(1):4-33 [20226390.001]
  • [Cites] J Clin Epidemiol. 2011 Dec;64(12):1303-10 [21802903.001]
  • [Cites] Lancet Neurol. 2016 Apr;15(5):455-532 [26987701.001]
  • (PMID = 28086755.001).
  • [ISSN] 1471-2318
  • [Journal-full-title] BMC geriatrics
  • [ISO-abbreviation] BMC Geriatr
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Keywords] NOTNLM ; Dementia / Meta-analysis / Systematic review / Vitamin D
  •  go-up   go-down


3. Tsiachristas A, Smith AD: B-vitamins are potentially a cost-effective population health strategy to tackle dementia: Too good to be true? Alzheimers Dement (N Y); 2016 Sep;2(3):156-161

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-vitamins are potentially a cost-effective population health strategy to tackle dementia: Too good to be true?
  • INTRODUCTION: To respond to the threat of dementia to public health and the economy, we need to prioritize research resources on strategies that would be the most effective.
  • In relation to the prevention of dementia, this article considers whether lowering plasma homocysteine by B-vitamin supplementation is one of the top priority and cost-effective treatments.
  • DISCUSSION: We anticipate that this provocative finding will be debated by scientists, clinicians, and policy makers and eventually be tested in future clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Technol Assess. 2001;5(1):1-137 [11262420.001]
  • [Cites] J Alzheimers Dis. 2011;26(4):735-44 [21709377.001]
  • [Cites] BMJ Open. 2015 Apr 13;5(4):e006648 [25869683.001]
  • [Cites] Int J Geriatr Psychiatry. 2010 Jan;25(1):82-90 [19484711.001]
  • [Cites] JAMA. 2008 Oct 15;300(15):1774-83 [18854539.001]
  • [Cites] Clin Chem. 2008 May;54(5):801-13 [18375482.001]
  • [Cites] Am J Psychiatry. 2007 Jun;164(6):861-7 [17541043.001]
  • [Cites] BMC Public Health. 2014 Jun 24;14:643 [24962204.001]
  • [Cites] Sci Rep. 2015 Jul 21;5:10585 [26194346.001]
  • [Cites] Prev Med. 2016 Apr;85:78-83 [26825761.001]
  • [Cites] Alzheimers Dement. 2013 Jan;9(1):58-62 [23141385.001]
  • [Cites] PLoS One. 2010 Sep 08;5(9):e12244 [20838622.001]
  • [Cites] J Intern Med. 2014 Mar;275(3):304-16 [24605810.001]
  • [Cites] Int J Geriatr Psychiatry. 2009 Jul;24(7):748-54 [19206079.001]
  • [Cites] JAMA. 2015 Apr 7;313(13):1325-35 [25771069.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9523-8 [23690582.001]
  • [Cites] Int J Geriatr Psychiatry. 2012 Jun;27(6):592-600 [21780182.001]
  • [Cites] Curr Alzheimer Res. 2010 Jun;7(4):358-67 [19939223.001]
  • [Cites] Clinicoecon Outcomes Res. 2011;3:189-95 [22046104.001]
  • [Cites] Annu Rev Nutr. 2016 Jul 17;36:211-39 [27431367.001]
  • [Cites] Lancet Neurol. 2016 Apr;15(5):455-532 [26987701.001]
  • [Cites] Clin Chem. 2004 Jan;50(1):3-32 [14709635.001]
  • [Cites] Lancet. 2007 Jan 20;369(9557):208-16 [17240287.001]
  • [Cites] J Alzheimers Dis. 2014;38(4):699-703 [24326609.001]
  • [Cites] Value Health. 2011 Jul-Aug;14(5):621-30 [21839398.001]
  • (PMID = 29067302.001).
  • [ISSN] 2352-8737
  • [Journal-full-title] Alzheimer's & dementia (New York, N. Y.)
  • [ISO-abbreviation] Alzheimers Dement (N Y)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; B-Vitamins / Cost-effectiveness / Dementia / Homocysteine / UK
  •  go-up   go-down


Advertisement
4. Kenawy S, Hegazy R, Hassan A, El-Shenawy S, Gomaa N, Zaki H, Attia A: Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. PLoS One; 2017;12(8):e0183565
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
  • Age-related dementia is one of the most devastating disorders affecting the elderly.
  • Recently, emerging data suggest that impaired insulin signaling is the major contributor in the development of Alzheimer's dementia (AD), which is the most common type of senile dementia.
  • Reversing of these harmful effects by the use of insulin-sensitizing drugs like Met and Saxa suggests their involvement in alleviation insulin resistance as the underlying pathology of AD and hence their potential use as anti-dementia drugs.
  • [MeSH-major] Adamantane / analogs & derivatives. Aging / pathology. Dementia / chemically induced. Dipeptides / toxicity. Galactose / toxicity. Hypoglycemic Agents / therapeutic use. Insulin Resistance. Metformin / therapeutic use

  • MedlinePlus Health Information. consumer health - Dementia.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gerontologist. 2016 Apr;56 Suppl 2:S167-77 [26994258.001]
  • [Cites] Oxid Med Cell Longev. 2014;2014:320513 [24669284.001]
  • [Cites] Nat Med. 2004 Jul;10(7):719-26 [15195085.001]
  • [Cites] J Lab Clin Med. 1963 May;61:882-8 [13967893.001]
  • [Cites] J Alzheimers Dis. 2016;51(4):1197-208 [26967226.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Mar;286(3):R431-44 [14761864.001]
  • [Cites] J Neurogenet. 2015;29(2-3):50-8 [26119401.001]
  • [Cites] Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a025932 [26931809.001]
  • [Cites] Neurobiol Learn Mem. 2011 Oct;96(3):432-42 [21907815.001]
  • [Cites] Mol Psychiatry. 2003 Sep;8(9):786-96 [12931206.001]
  • [Cites] Mol Neurobiol. 2017 Jan;54(1):255-271 [26738855.001]
  • [Cites] J Neurol Sci. 2006 Jun 15;245(1-2):21-33 [16631207.001]
  • [Cites] Mol Psychiatry. 2010 Nov;15(11):1046-52 [20966918.001]
  • [Cites] Vascul Pharmacol. 2016 Jan;76:62-71 [26455387.001]
  • [Cites] Neuropharmacology. 2016 Feb;101:123-36 [26211973.001]
  • [Cites] J Diabetes Complications. 2016 May-Jun;30(4):746-52 [26796432.001]
  • [Cites] J Ethnopharmacol. 2016 Feb 17;179:162-9 [26721223.001]
  • [Cites] Kidney Res Clin Pract. 2016 Jun;35(2):69-77 [27366660.001]
  • [Cites] Gerontologist. 1997 Apr;37(2):150-6 [9127971.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2016;15(3):329-36 [26831258.001]
  • [Cites] Pharmacol Biochem Behav. 2012 Jun;101(4):564-74 [22425595.001]
  • [Cites] J Alzheimers Dis. 2005 Dec;8(3):247-68 [16340083.001]
  • [Cites] Curr Top Med Chem. 2016;16(5):485-92 [26268336.001]
  • [Cites] Behav Brain Res. 2011 Jun 20;220(1):30-41 [21262264.001]
  • [Cites] Expert Rev Neurother. 2010 May;10(5):683-91 [20420489.001]
  • [Cites] J Neurochem. 2004 Jun;89(6):1313-7 [15189333.001]
  • [Cites] Neuropharmacology. 2013 Sep;72:291-300 [23603201.001]
  • [Cites] Expert Opin Investig Drugs. 2015 Mar;24(3):393-9 [25586103.001]
  • [Cites] Curr Atheroscler Rep. 2016 Apr;18(4):16 [26888066.001]
  • [Cites] J Neuroimmunol. 1999 Jan 1;93(1-2):182-93 [10378882.001]
  • [Cites] Mol Neurobiol. 2016 Apr;53(3):1741-1752 [25744568.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):248-52 [2573290.001]
  • [Cites] Biotherapy. 1991;3(2):127-33 [2054253.001]
  • [Cites] Brain Res Bull. 2017 Jul;133:88-96 [27316747.001]
  • [Cites] Alzheimers Dement. 2016 Jun;12(6):719-32 [27179961.001]
  • [Cites] J Vis Exp. 2011 Jul 20;(53):null [21808223.001]
  • [Cites] Arch Neurol. 2011 Jan;68(1):51-7 [20837822.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] Cell Cycle. 2014;13(6):898-909 [24552807.001]
  • [Cites] J Pharm Sci. 1983 May;72(5):465-92 [6345750.001]
  • [Cites] J Nutr Health Aging. 2016 Apr;20(4):439-45 [26999245.001]
  • [Cites] Eur J Pharmacol. 2011 Jun 25;660(2-3):363-7 [21497160.001]
  • [Cites] Rev Neurosci. 2011;22(3):285-94 [21568789.001]
  • [Cites] J Cell Sci. 2001 Apr;114(Pt 8):1429-30 [11282018.001]
  • [Cites] Ann N Y Acad Sci. 2008 Apr;1126:147-51 [18448809.001]
  • [Cites] Lancet. 1994 Sep 17;344(8925):769-72 [7916070.001]
  • [Cites] J Alzheimers Dis. 2016;51(2):515-23 [26890783.001]
  • [Cites] PLoS One. 2015 Dec 02;10(12):e0143814 [26629991.001]
  • [Cites] Biomed Rep. 2016 May;4(5):519-522 [27123241.001]
  • [Cites] Mol Neurobiol. 2013 Dec;48(3):556-70 [23546742.001]
  • (PMID = 28832656.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Dipeptides; 0 / Hemoglobin A, Glycosylated; 0 / Hypoglycemic Agents; 0 / Nerve Tissue Proteins; 9100L32L2N / Metformin; 9GB927LAJW / saxagliptin; PJY633525U / Adamantane; X2RN3Q8DNE / Galactose
  •  go-up   go-down


5. Xu G, Bai F, Lin X, Wang Q, Wu Q, Sun S, Jiang C, Liang Q, Gao B: Association between Antihypertensive Drug Use and the Incidence of Cognitive Decline and Dementia: A Meta-Analysis of Prospective Cohort Studies. Biomed Res Int; 2017;2017:4368474

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between Antihypertensive Drug Use and the Incidence of Cognitive Decline and Dementia: A Meta-Analysis of Prospective Cohort Studies.
  • Background: Antihypertensive drug use is inconsistently associated with the risk of dementia, Alzheimer's disease, cognitive impairment, and cognitive decline.
  • Only prospective cohort studies that reported effect estimates with corresponding 95% confidence intervals (CIs) of dementia, Alzheimer's disease, cognitive impairment, and cognitive decline for antihypertensive drug use versus not using antihypertensive drugs were included.
  • Overall, participants who received antihypertensive drugs had lower incidence of dementia (relative risk [RR]: 0.86; 95% CI: 0.75-0.99; <i>p</i> = 0.033), while there was no significant effect on the incidence of Alzheimer's disease (RR: 0.83; 95% CI: 0.64-1.09; <i>p</i> = 0.154), cognitive impairment (RR: 0.89; 95% CI: 0.57-1.38; <i>p</i> = 0.596), and cognitive decline (RR: 1.11; 95% CI: 0.86-1.43; <i>p</i> = 0.415).
  • Further, the incidence of Alzheimer's disease might be affected by antihypertensive drug use in participants with specific characteristics.
  • Conclusions: Antihypertensive drug use was associated with a significantly reduced risk of dementia, but not with the risk of Alzheimer's disease, cognitive impairment, and cognitive decline.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stroke. 2004 Aug;35(8):1810-5 [15232128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3227-32 [9501245.001]
  • [Cites] Arch Neurol. 2010 May;67(5):564-9 [20457955.001]
  • [Cites] Stroke. 2002 Jan;33(1):26-30 [11779884.001]
  • [Cites] Circulation. 2011 Mar 15;123(10):1138-43 [21233236.001]
  • [Cites] Diabetologia. 2008 Feb;51(2):241-8 [18060658.001]
  • [Cites] Int J Clin Pract. 2011 Dec;65(12):1295-305 [22093537.001]
  • [Cites] Biometrics. 1994 Dec;50(4):1088-101 [7786990.001]
  • [Cites] Neurology. 2016 Aug 9;87(6):601-8 [27402894.001]
  • [Cites] Neurology. 2013 Sep 3;81(10 ):896-903 [23911756.001]
  • [Cites] J Am Coll Cardiol. 2011 May 17;57(20):2037-114 [21524875.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Hypertension. 2009 Aug;54(2):233-40 [19564551.001]
  • [Cites] J Alzheimers Dis. 2008 May;13(4):421-35 [18487850.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1559-73 [12111920.001]
  • [Cites] Age (Dordr). 2013 Apr;35(2):441-53 [22203459.001]
  • [Cites] Am J Hypertens. 2016 Feb;29(2):202-16 [26137952.001]
  • [Cites] BMJ. 2013 Jul 29;347:f4600 [23900315.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Arch Neurol. 2006 May;63(5):686-92 [16533956.001]
  • [Cites] Neurology. 2006 May 9;66(9):1399-404 [16682673.001]
  • [Cites] J Am Geriatr Soc. 2013 Dec;61(12):2168-73 [24479146.001]
  • [Cites] Aging Cell. 2007 Jun;6(3):267-73 [17517038.001]
  • [Cites] Neurology. 2005 Aug 23;65(4):545-51 [16116114.001]
  • [Cites] Neurobiol Aging. 2001 May-Jun;22(3):407-12 [11378246.001]
  • [Cites] Med Decis Making. 2005 Nov-Dec;25(6):646-54 [16282215.001]
  • [Cites] BMJ. 1997 Sep 13;315(7109):629-34 [9310563.001]
  • [Cites] Arch Neurol. 2011 Sep;68(9):1185-90 [21555601.001]
  • [Cites] BMJ. 2009 Nov 24;339:b4567 [19934192.001]
  • [Cites] Atherosclerosis. 2014 Mar;233(1):19-26 [24529116.001]
  • [Cites] Blood Press. 2005;14(6):353-8 [16403689.001]
  • [Cites] J Neurosci. 1992 Feb;12(2):376-89 [1346802.001]
  • [Cites] PLoS Med. 2009 Jul 21;6(7):e1000097 [19621072.001]
  • (PMID = 29094046.001).
  • [ISSN] 2314-6141
  • [Journal-full-title] BioMed research international
  • [ISO-abbreviation] Biomed Res Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


6. Friberg L, Rosenqvist M: Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J; 2017 Oct 24;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less dementia with oral anticoagulation in atrial fibrillation.
  • Aims: The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection.
  • The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect.
  • Methods and results: Retrospective registry study of all patients with hospital diagnosis of AF and no previous diagnosis of dementia in Sweden between 2006 and 2014.
  • Patients on anticoagulant treatment at baseline was associated with 29% lower risk of dementia than patients without anticoagulant treatment [hazard ratio (HR) 0.71, 95% confidence intervals (95% CI) 0.68-0.74] and 48% lower risk analysed on treatment (HR 0.52, 95% CI 0.50-055).
  • Conclusion: The risk of dementia is higher without oral anticoagulant treatment in patients with AF.


7. Yang JS, Wu XH, Yu HG, Teng LS: Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats. Inflammopharmacology; 2017 Aug;25(4):471-484
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats.
  • Our aim was to investigate whether tangeretin, a citrus flavonoid, was able to prevent neuroinflammation and improve dementia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced rodent model of Parkinson's disease (PD).
  • The experimental data suggest tangeretin as an effective candidate drug with potential for prevention and treatment of neuroinflammation and dementia associated with PD.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Behav Brain Res. 2011 Jun 1;219(2):280-90 [21262271.001]
  • [Cites] Neurotox Res. 2016 Feb;29(2):275-87 [26607911.001]
  • [Cites] Neurosci Lett. 2000 Jun 23;287(2):117-20 [10854726.001]
  • [Cites] Behav Brain Res. 2008 Apr 9;188(2):310-5 [18178264.001]
  • [Cites] J Neurosci Methods. 2005 Oct 15;148(1):78-87 [15939479.001]
  • [Cites] Behav Brain Res. 1988 Nov 1;31(1):47-59 [3228475.001]
  • [Cites] Eur J Neurosci. 2001 Feb;13(3):529-38 [11168560.001]
  • [Cites] J Agric Food Chem. 2008 Aug 13;56(15):6185-205 [18593176.001]
  • [Cites] Clin Neurosci Res. 2006 Dec 6;6(5):261-281 [18060039.001]
  • [Cites] Neuroscience. 2004;127(2):289-300 [15262320.001]
  • [Cites] J Neurol. 2000 Apr;247 Suppl 2:II25-35 [10991662.001]
  • [Cites] Glia. 2005 Nov 1;52(2):144-52 [15920722.001]
  • [Cites] Trends Mol Med. 2013 Mar;19(3):187-96 [23318001.001]
  • [Cites] Acta Anaesthesiol Scand. 2013 Mar;57(3):380-90 [23186353.001]
  • [Cites] Front Biosci. 2003 Sep 01;8:s992-7 [12957858.001]
  • [Cites] Behav Brain Res. 2014 Jul 15;268:177-84 [24755306.001]
  • [Cites] Eur J Neurosci. 2003 Sep;18(5):1175-88 [12956716.001]
  • [Cites] Neurobiol Aging. 2012 Aug;33(8):1777-91 [21524431.001]
  • [Cites] Neurosci Lett. 1998 Jun 26;250(1):25-8 [9696057.001]
  • [Cites] Neuropsychologia. 2003;41(5):565-74 [12559149.001]
  • [Cites] J Neurosci. 2005 Mar 2;25(9):2322-9 [15745958.001]
  • [Cites] Behav Brain Res. 2001 Sep 28;124(1):9-18 [11423161.001]
  • [Cites] FASEB J. 2003 Mar;17 (3):500-2 [12631585.001]
  • [Cites] Eur J Pharmacol. 2003 Dec 15;482(1-3):215-22 [14660025.001]
  • [Cites] Neuroscience. 1999 Jan;88(1):1-16 [10051185.001]
  • [Cites] Exp Neurol. 2005 Oct;195(2):322-9 [16005872.001]
  • [Cites] Lancet Neurol. 2003 Apr;2(4):229-37 [12849211.001]
  • [Cites] Parkinsonism Relat Disord. 2004 May;10 Suppl 1:S3-7 [15109580.001]
  • [Cites] Mediators Inflamm. 2013;2013:952375 [23935251.001]
  • [Cites] FASEB J. 2006 Apr;20(6):670-82 [16581975.001]
  • [Cites] Restor Neurol Neurosci. 2013;31(1):87-97 [23047495.001]
  • [Cites] J Neuroimmunol. 2008 Nov 15;204(1-2):43-51 [18817984.001]
  • [Cites] Food Chem Toxicol. 2014 Sep;71:176-82 [24955543.001]
  • [Cites] Cancer Chemother Pharmacol. 2015 Feb;75(2):263-72 [25431347.001]
  • [Cites] Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S210-2 [22166438.001]
  • [Cites] J Food Sci. 2016 May;81(5):H1320-7 [27095513.001]
  • [Cites] Neuroimage. 2006 Oct 15;33(1):374-82 [16904344.001]
  • [Cites] Behav Neurosci. 1988 Oct;102(5):748-59 [2904271.001]
  • [Cites] Acta Neuropathol. 2003 Dec;106(6):518-26 [14513261.001]
  • [Cites] Behav Brain Res. 2012 Apr 1;229(1):41-7 [22227506.001]
  • [Cites] Neurobiol Learn Mem. 2008 Feb;89(2):192-8 [17702614.001]
  • [Cites] Brain Res Bull. 2001 May 1;55(1):101-6 [11427344.001]
  • [Cites] J Neurosci. 2004 May 12;24(19):4596-604 [15140931.001]
  • [Cites] Hippocampus. 2005;15(8):1050-6 [16145694.001]
  • [Cites] J Neurosci Res. 1999 May 15;56(4):441-6 [10340751.001]
  • [Cites] Behav Brain Res. 2006 Apr 25;169(1):142-9 [16455144.001]
  • [Cites] Curr Alzheimer Res. 2005 Jul;2(3):355-65 [15974901.001]
  • [Cites] Neurobiol Learn Mem. 2008 May;89(4):522-32 [18304843.001]
  • [Cites] Neuroscience. 2005;133(3):831-40 [15893432.001]
  • [Cites] Prog Neurobiol. 2000 Sep;62(1):63-88 [10821982.001]
  • [Cites] Immunopharmacology. 1998 Jun;39(3):167-80 [9754903.001]
  • [Cites] Neuropharmacology. 2008 Mar;54(3):620-7 [18164319.001]
  • [Cites] Neuroreport. 2001 Dec 4;12(17):3871-5 [11726811.001]
  • [Cites] J Neurosci. 2000 Aug 1;20(15):5715-23 [10908611.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1988 Dec;51(12):1498-502 [3221216.001]
  • [Cites] Behav Brain Res. 2010 Mar 17;208(1):38-46 [19900486.001]
  • [Cites] Neurosci Res. 2006 Sep;56(1):96-102 [16846658.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1404-10 [15851731.001]
  • [Cites] Exp Neurol. 2005 Mar;192(1):134-41 [15698627.001]
  • [Cites] Brain Res. 2000 Mar 31;860(1-2):190-4 [10727642.001]
  • [Cites] Biomed Pharmacother. 2016 Jul;81:491-6 [27261630.001]
  • [Cites] Neuropharmacology. 2015 Apr;91:43-56 [25499022.001]
  • [Cites] Nat Neurosci. 2001 Jul;4(7):702-10 [11426226.001]
  • [Cites] J Neural Transm Suppl. 2000;(58):143-51 [11128604.001]
  • [Cites] Am J Psychiatry. 1995 Sep;152(9):1291-7 [7653683.001]
  • [Cites] Ann Neurol. 1999 Oct;46(4):598-605 [10514096.001]
  • [Cites] Dev Neurosci. 1998;20(1):1-18 [9600386.001]
  • [Cites] Neurobiol Dis. 2008 Nov;32(2):319-27 [18718537.001]
  • [Cites] Nat Rev Neurol. 2010 Apr;6(4):193-201 [20234358.001]
  • [Cites] J Am Assoc Lab Anim Sci. 2011 Jan;50(1):41-5 [21333162.001]
  • [Cites] Behav Neurosci. 2009 Dec;123(6):1261-70 [20001109.001]
  • [Cites] Pharmacol Biochem Behav. 2010 Apr;95(2):158-65 [20064549.001]
  • [Cites] Eur J Pharmacol. 2008 Oct 10;594(1-3):101-8 [18674531.001]
  • [Cites] Phytother Res. 2013 Apr;27(4):564-71 [22678994.001]
  • [Cites] Parkinsonism Relat Disord. 2005 Jun;11 Suppl 1:S9-S15 [15885630.001]
  • [Cites] Br J Pharmacol. 2007 Apr;150(8):963-76 [17339843.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):141-50 [15619128.001]
  • [Cites] Mol Genet Metab. 1998 Feb;63(2):142-7 [9562968.001]
  • [Cites] Glia. 2004 May;46(4):402-9 [15095370.001]
  • [Cites] Neurotoxicology. 2012 Mar;33(2):147-55 [22281204.001]
  • [Cites] Neurosci Lett. 2003 May 1;341(2):87-90 [12686372.001]
  • [Cites] Mov Disord. 2006 Sep;21(9):1483-7 [16705661.001]
  • [Cites] Pharmacol Biochem Behav. 2012 Jul;102(1):64-71 [22487770.001]
  • [Cites] J Neuroimmune Pharmacol. 2016 Jun;11(2):294-305 [26899309.001]
  • (PMID = 28577132.001).
  • [ISSN] 1568-5608
  • [Journal-full-title] Inflammopharmacology
  • [ISO-abbreviation] Inflammopharmacology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) / Dementia / Inflammatory cytokines / Neurodegeneration / Parkinson’s disease / Tangeretin
  •  go-up   go-down


8. Allers K, Dörks M, Schmiemann G, Hoffmann F: Antipsychotic drug use in nursing home residents with and without dementia: keep an eye on the pro re nata medication. Int Clin Psychopharmacol; 2017 Jul;32(4):213-218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antipsychotic drug use in nursing home residents with and without dementia: keep an eye on the pro re nata medication.
  • Behavioral and psychological symptoms of dementia often lead to the prescription of antipsychotics, especially in nursing homes, but their use remains controversial.
  • This study aimed to assess antipsychotic drug use in residents with dementia compared with those without dementia.
  • Overall, 57.5% of the 837 residents had a diagnosis of dementia and 47.0% of residents with dementia and 19.5% of those without dementia received antipsychotics.
  • 35.9% of all antipsychotics in residents with dementia were prescribed as pro re nata (PRN) compared with 23.0% for residents without dementia.
  • The adjusted logistic regression showed a significant association between the prescription of antipsychotics and dementia (odds ratio: 3.58, 95% confidence interval: 2.45-5.25) as well as severe care dependency (odds ratio: 1.68, 95% confidence interval: 1.10-2.55).
  • Despite safety warnings, antipsychotics are still frequently prescribed to residents with dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28346296.001).
  • [ISSN] 1473-5857
  • [Journal-full-title] International clinical psychopharmacology
  • [ISO-abbreviation] Int Clin Psychopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Ammann EM, Pottala JV, Robinson JG, Espeland MA, Harris WS: Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). Prostaglandins Leukot Essent Fatty Acids; 2017 Jun;121:68-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS).
  • OBJECTIVE: To assess whether red blood cell (RBC) docosahexaenoic acid and eicosapentaenoic acid (DHA+EPA) levels have a protective association with the risk of dementia in older women.
  • Cox regression was used to quantify the association between RBC DHA+EPA and the risk of probable dementia, independent of major dementia risk factors.
  • RESULTS: During a median follow-up period of 9.8 years, 587 incident cases of probable dementia were identified.
  • After adjusting for demographic, clinical, and behavioral risk factors, a one standard deviation increase in DHA+EPA levels was associated with a significantly lower risk of dementia (HR = 0.92, 95% CI: 0.84, 1.00; p < 0.05).
  • For women with high DHA+EPA exposure (1SD above mean) compared to low exposure (1SD below mean), the adjusted 15-year absolute risk difference for dementia was 2.1% (95% CI: 0.2%, 4.0%).
  • DISCUSSION: Higher levels of DHA+EPA may help protect against the development of dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • [Cites] Epidemiology. 2010 Jan;21(1):13-5 [20010207.001]
  • [Cites] Biochim Biophys Acta. 2015 Jan;1848(1 Pt B):211-9 [24820775.001]
  • [Cites] JAMA. 2016 Feb 2;315(5):489-97 [26836731.001]
  • [Cites] J Alzheimers Dis. 2003 Aug;5(4):315-22 [14624027.001]
  • [Cites] Alzheimers Res Ther. 2016 Jun 30;8:25 [27358067.001]
  • [Cites] J Nutr Health Aging. 2011 Jan;15(1):25-31 [21267518.001]
  • [Cites] J Alzheimers Dis. 2012;29(3):691-7 [22466064.001]
  • [Cites] Lipids. 2012 Sep;47(9):835-46 [22782370.001]
  • [Cites] Biostatistics. 2006 Jan;7(1):29-40 [15923407.001]
  • [Cites] Atherosclerosis. 2013 May;228(1):181-7 [23466070.001]
  • [Cites] JAMA. 2004 Jun 23;291(24):2947-58 [15213206.001]
  • [Cites] FEBS Lett. 2016 Feb;590(4):582-91 [26821608.001]
  • [Cites] Biochim Biophys Acta. 2015 Apr;1851(4):397-413 [25139562.001]
  • [Cites] Prev Med. 2004 Jul;39(1):212-20 [15208005.001]
  • [Cites] Nat Neurosci. 2012 Jan 29;15(3):349-57 [22286176.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2010 Feb 25;56(1):59-82 [20196971.001]
  • [Cites] Am J Clin Nutr. 2008 Jul;88(1):216-23 [18614744.001]
  • [Cites] Am J Clin Nutr. 2016 Feb;103(2):330-40 [26718417.001]
  • [Cites] J Clin Psychiatry. 2012 Sep;73(9):1245-54 [22938939.001]
  • [Cites] Am J Clin Nutr. 2008 Feb;87(2):449-54 [18258638.001]
  • [Cites] Biomed Res Int. 2015;2015:172801 [26301243.001]
  • [Cites] Am J Clin Nutr. 2003 Apr;77(4):803-8 [12663275.001]
  • [Cites] Neurosci Biobehav Rev. 2015 Jan;48:1-9 [25446949.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1701-12 [15082697.001]
  • [Cites] JAMA. 2002 Jul 17;288(3):321-33 [12117397.001]
  • [Cites] FEBS J. 2011 Oct;278(20):3905-17 [21722314.001]
  • [Cites] Diabetes Care. 2015 Dec;38(12 ):2316-24 [26486190.001]
  • [Cites] Aust Prescr. 2015 Apr;38(2):60-3 [26648618.001]
  • [Cites] J Clin Psychiatry. 1987 Aug;48(8):314-8 [3611032.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):178-87 [10192650.001]
  • [Cites] Am J Clin Nutr. 2007 Apr;85(4):1103-11 [17413112.001]
  • [Cites] Arch Neurol. 1998 Mar;55(3):360-5 [9520010.001]
  • [Cites] Eur J Clin Nutr. 2014 Apr;68(4):503-9 [24398640.001]
  • [Cites] Neurology. 2014 Feb 4;82(5):435-42 [24453077.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6 Suppl):1467S-1476S [16841856.001]
  • [Cites] Lipids. 2000 Dec;35(12):1305-12 [11201991.001]
  • [Cites] Neurology. 2012 Feb 28;78(9):658-64 [22371413.001]
  • [Cites] Neurology. 2013 Oct 22;81(17):1484-91 [24068783.001]
  • [Cites] JAMA. 2004 Jun 23;291(24):2959-68 [15213207.001]
  • [Cites] Biochem Pharmacol. 2014 Apr 15;88(4):640-51 [24398425.001]
  • [Cites] Neurology. 1997 Dec;49(6):1498-504 [9409336.001]
  • [Cites] FASEB J. 2015 Jul;29(7):2681-9 [25805829.001]
  • [Cites] Neurobiol Aging. 2012 Jul;33(7):1482.e17-29 [22305186.001]
  • [Cites] Arch Neurol. 2006 Nov;63(11):1545-50 [17101822.001]
  • [Cites] Nutr Res. 2016 Sep;36(9):989-994 [27632919.001]
  • [Cites] Am J Clin Nutr. 2008 Sep;88(3):714-21 [18779288.001]
  • (PMID = 28651700.001).
  • [ISSN] 1532-2823
  • [Journal-full-title] Prostaglandins, leukotrienes, and essential fatty acids
  • [ISO-abbreviation] Prostaglandins Leukot. Essent. Fatty Acids
  • [Language] eng
  • [Grant] United States / WHI NIH HHS / WH / HHSN268200900036C
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Keywords] NOTNLM ; All cognitive disorders/dementia / Alzheimer's Disease / Biomarkers / Cohort studies / Omega-3 fatty acids / Women
  •  go-up   go-down


10. Chen Q, Ermann A, Shad MU: Effectiveness of Dextromethorphan/Quinidine in Frontotemporal Dementia. Am J Geriatr Psychiatry; 2017 Oct 19;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of Dextromethorphan/Quinidine in Frontotemporal Dementia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29132987.001).
  • [ISSN] 1545-7214
  • [Journal-full-title] The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • [ISO-abbreviation] Am J Geriatr Psychiatry
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down






Advertisement